The stock of NeuroPace Inc (NPCE) has gone down by -5.03% for the week, with a -23.26% drop in the past month and a -23.26% drop in the past quarter. The volatility ratio for the week is 6.96%, and the volatility levels for the past 30 days are 6.58% for NPCE. The simple moving average for the last 20 days is -7.76% for NPCE’s stock, with a simple moving average of -5.16% for the last 200 days.
Is It Worth Investing in NeuroPace Inc (NASDAQ: NPCE) Right Now?
NPCE has 36-month beta value of 1.94. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy”, 2 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for NPCE is 22.70M, and currently, short sellers hold a 1.57% ratio of that float. The average trading volume of NPCE on July 04, 2025 was 352.74K shares.
NPCE stock’s latest price update
The stock price of NeuroPace Inc (NASDAQ: NPCE) has dropped by -0.29% compared to previous close of $10.42. Despite this, the company has seen a fall of -5.03% in its stock price over the last five trading days. prnewswire.com reported 2025-07-02 that NEW YORK, July 2, 2025 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Analysts’ Opinion of NPCE
Many brokerage firms have already submitted their reports for NPCE stocks, with H.C. Wainwright repeating the rating for NPCE by listing it as a “Buy”. The predicted price for NPCE in the upcoming period, according to H.C. Wainwright is $18 based on the research report published on May 28, 2025 of the current year 2025.
UBS, on the other hand, stated in their research note that they expect to see NPCE reach a price target of $17. The rating they have provided for NPCE stocks is “Buy” according to the report published on January 21st, 2025.
Leerink Partners gave a rating of “Outperform” to NPCE, setting the target price at $22 in the report published on January 30th of the previous year.
NPCE Trading at -18.16% from the 50-Day Moving Average
After a stumble in the market that brought NPCE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.24% of loss for the given period.
Volatility was left at 6.58%, however, over the last 30 days, the volatility rate increased by 6.96%, as shares sank -21.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.03% lower at present.
During the last 5 trading sessions, NPCE fell by -5.03%, which changed the moving average for the period of 200-days by +39.84% in comparison to the 20-day moving average, which settled at $11.26. In addition, NeuroPace Inc saw 41.94% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NPCE starting from ORBIMED ADVISORS LLC, who sold 168,136 shares at the price of $15.85 back on May 14 ’25. After this action, ORBIMED ADVISORS LLC now owns 3,238,199 shares of NeuroPace Inc, valued at $2,665,333 using the latest closing price.
Morrell Martha, the CHIEF MEDICAL OFFICER of NeuroPace Inc, sale 78,334 shares at $13.72 during a trade that took place back on Feb 21 ’25, which means that Morrell Martha is holding 81,993 shares at $1,074,844 based on the most recent closing price.
Stock Fundamentals for NPCE
Current profitability levels for the company are sitting at:
- -0.23% for the present operating margin
- 0.75% for the gross margin
The net margin for NeuroPace Inc stands at -0.22%. The total capital return value is set at -0.2%. Equity return is now at value -128.49%, with -23.73% for asset returns.
Based on NeuroPace Inc (NPCE), the company’s capital structure generated 0.75 points at debt to capital in total, while cash flow to debt ratio is standing at -0.24. The debt to equity ratio resting at 3.01. The interest coverage ratio of the stock is -4.39.
Currently, EBITDA for the company is -16.57 million with net debt to EBITDA at -2.98. When we switch over and look at the enterprise to sales, we see a ratio of 4.44. The receivables turnover for the company is 5.46for trailing twelve months and the total asset turnover is 0.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.63.
Conclusion
To put it simply, NeuroPace Inc (NPCE) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
